Vir Biotechnology Inc (VIR)

Return on total capital

Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019
Earnings before interest and tax (EBIT) (ttm) US$ in thousands -684,305 -695,791 -314,095 -324,131 833,070 1,555,324 1,306,975 1,593,214 420,751 -259,405 -293,635 -383,703 -296,980 -252,335 -212,400
Long-term debt US$ in thousands
Total stockholders’ equity US$ in thousands 1,590,240 1,675,080 1,810,210 1,970,760 2,077,960 2,149,860 1,952,010 2,001,010 1,431,850 876,274 737,325 650,951 716,852 812,355 563,779 380,333 423,942 -280,797
Return on total capital -43.03% -41.54% -17.35% -16.45% 40.09% 72.35% 66.96% 79.62% 29.39% -29.60% -39.82% -58.94% -41.43% -31.06% -37.67%

December 31, 2023 calculation

Return on total capital = EBIT (ttm) ÷ (Long-term debt + Total stockholders’ equity)
= $-684,305K ÷ ($—K + $1,590,240K)
= -43.03%

Vir Biotechnology Inc's return on total capital has shown significant fluctuations over the past eight quarters. The return on total capital was negative during the most recent two quarters, Q4 2023 and Q3 2023, at -43.03% and -41.54% respectively, indicating that the company is generating a lower return relative to its total capital base. This negative trend continued from the positive returns seen in the previous quarters of 2022.

The return on total capital experienced a sharp decline in Q2 2023 at -17.35% compared to the previous quarter, Q1 2023, at -16.45%. This downward trend contrasts with the robust performance in 2022, where the return on total capital exceeded 40% in each quarter.

The substantial decrease in the return on total capital in 2023 raises concerns about the company's ability to efficiently utilize its capital resources to generate profits. Investors and stakeholders may closely monitor future financial performance to assess the company's strategic direction and operational efficiency.


Peer comparison

Dec 31, 2023